Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)

Gregory Y. H. Lip, Jean Philippe Collet, Raffaele de Caterina, Laurent Fauchier, Deirdre A. Lane, Torben B. Larsen, Francisco Marin, Joao Morais, Calambur Narasimhan, Brian Olshansky, Luc Pierard, Tatjana Potpara, Nizal Sarrafzadegan, Karen Sliwa, Gonzalo Varela, Gemma Vilahur, Thomas Weiss, Giuseppe Boriani, Bianca Rocca

1 Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom
2 Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
3 ACTION Study Group, Institut De Cardiologie, Hôpital Pitié-Salpêtrière (APHP), Sorbonne Université, Paris, France
4 Institute of Cardiology, ’G. d’Annunzio’ University, Chieti, Italy
5 Centre Hospitalier Universitaire Trousseau et Faculté de Medicine, Université François Rabelais, Tours, France
6 Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark
7 Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
8 Department of Cardiology, Leiria Hospital Centre, Leiria, Portugal
9 Department of Cardiac Electrophysiology, CARE Hospital, Hyderabad, Andhra Pradesh, India
10 Clinical Cardiac Electrophysiology, Cardiology, Mercy Medical Center, Mason City, Iowa, United States
11 Department of Cardiology, University Hospital Sart-Tilman, Liege, Belgium
12 Cardiology Clinic, Clinical Center of Serbia, University of Belgrade School of Medicine, Belgrade, Serbia
13 Isfahan Cardiovascular Research Center (WHO Collaborating Center), Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
14 School of Population and Public Health, University of British Columbia, Vancouver, Canada
15 Hatter Institute for Cardiovascular Research in Africa, Faculty of Health Sciences, University of Cape Town, South Africa
16 Mary McKillop Institute, ACU, Melbourne, Australia
17 Servicio de Electrofisiología, Centro Cardiovascular Casa de Galicia, Hidalgos, Uruguay
18 Cardiovascular Science Institute (ICCC), CIBERCV, IIB-Sant Pau, Hospital de la Sant Pau, Barcelona, Spain
19 Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria
20 Faculty of Medicine, Sigmund Freud University, Vienna, Austria
21 Department of Cardiology, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
22 Institute of Pharmacology, Catholic University School of Medicine, Rome, Italy

Address for correspondence Gregory Y. H. Lip, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom (e-mail: g.y.h.lip@bham.ac.uk).

Copyright © 2017 Schattauer DOI https://doi.org/10.1160/TH-17-10-0709.
ISSN 0340-6245.
Management strategies for patients with atrial fibrillation (AF) in association with valvular heart disease (VHD) have been less informed by randomized trials, which have largely focused on ‘non-valvular AF’ patients. Thromboembolic risk also varies according to valve lesion and may also be associated with CHA₂DS₂-VASc score risk factor components, rather than only the valve disease being causal.

Given the need to provide expert recommendations for professionals participating in the care of patients presenting with AF and associated VHD, a task force was convened by the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group (WG) on Thrombosis, with representation from the ESC WG on Valvular Heart Disease, Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) with the remit to comprehensively review the published evidence, and to produce a consensus document on the management of patients with AF and associated VHD, with up-to-date consensus statements for clinical practice for different forms of VHD, based on the principles of evidence-based medicine.

This is an executive summary of a consensus document which proposes that the term ‘valvular AF’ is outdated and given that any definition ultimately relates to the evaluated practical use of oral anticoagulation (OAC) type, we propose a functional EHRA (Evaluated Heartvalves, Rheumatic or Artificial) categorization in relation to the type of OAC use in patients with AF, as follows: (1) EHRA (Evaluated Heartvalves, Rheumatic or Artificial) type 1 VHD, which refers to AF patients with VHD needing therapy with a vitamin K antagonist (VKA)’ and (2) EHRA (Evaluated Heartvalves, Rheumatic or Artificial) type 2 VHD, which refers to AF patients with VHD needing therapy with a VKA or a non-VKA oral anticoagulant also taking into consideration CHA₂DS₂-VASc score risk factor components.

For this consensus document, we recognize the uncertainty in terminology, and our scope largely relates to AF associated with ‘haemodynamically significant’ rheumatic VHD (i.e. severe enough to impact on patient’s survival or necessitate an intervention or surgery) or prosthetic mechanical heart valves. Nonetheless, TE risk varies according to valve lesion and may be associated with CHA₂DS₂-VASc score risk factor components, rather than the valve disease per se being causal. TE risk may also be influenced not only by type but also by the severity of the lesion. For example, the degree of MR may matter when it comes to risk of TE, as some studies suggest that mild (grade 1) MR is associated with a 2.7-fold increased risk of stroke/TE, while severe forms may possibly have a ‘protective’ effect (HR: 0.45 for stroke and 0.27 for left atrial stasis). An appropriate definition of ‘valvular AF’ would need to identify a subgroup of patients with similar pathophysiology of TE, TE risk and treatment strategies.

This is an executive summary of a consensus document which proposes that the term ‘valvular AF’ is outdated and given that any definition ultimately relates to the evaluated practical use of oral anticoagulation (OAC) type, we propose a functional EHRA (Evaluated Heartvalves, Rheumatic or Artificial) categorization in relation to the type of OAC use in
patients with AF (see Summary box). This classification would have the advantage that it may easily evolve or be updated (type 1 may become type 2 or vice versa) when there are new results. For example, transcatheter mitral valve interventions (TMVI; e.g. to include both MitraClip and mitral valve replacement) are emerging as a possible therapeutic option, but more data are awaited especially in relation to OAC use. Also, EHRA type I is broadly similar to the previously described MARM-AF.

Summary box

| Definition | The term ‘valvular AF’ is outdated and given that any definition ultimately relates to the evaluated practical use of oral anticoagulation (OAC) type, we propose a functional EHRA (Evaluated Heartvalves, Rheumatic or Artificial) categorization in relation to the type of OAC use in patients with AF.

EHRA (Evaluated Heartvalves, Rheumatic or Artificial) type 1 VHD, which refers to AF patients with ‘VHD needing therapy with a vitamin K antagonist (VKA)’

- Mitral stenosis (moderate-severe, of rheumatic origin)
- Mechanical prosthetic valve replacement

EHRA (Evaluated Heartvalves, Rheumatic or Artificial) type 2 VHD, which refers to AF patients with ‘VHD needing therapy with a VKA or a NOAC’, also taking into consideration CHA2DS2-VASC score risk factor components

- Mitral regurgitation
- Mitral valve repair
- Aortic stenosis
- Aortic regurgitation
- Tricuspid regurgitation
- Tricuspid stenosis
- Pulmonary regurgitation
- Pulmonic stenosis
- Bioprosthesis valve replacements
- Transaortic valve intervention (TAVI)

| Evidence Review |

This document was prepared by the Task Force with representation from EHRA, HRS, APHRS and SOLAECE. The document was peer-reviewed by official external reviewers representing EHRA, HRS, APHRS, SOLAECE and WGs. Consensus statements are evidence based, and derived primarily from published data. In controversial areas, or with respect to issues without evidence other than usual clinical practice, a consensus was achieved by agreement of the expert panel after thorough deliberation.

Differently to guidelines, we opted for an easier and user-friendly system of ranking using ‘coloured hearts’ that should allow physicians to easily assess the current status of the evidence and consequent guidance (–Table 1). This EHRA grading of consensus statements does not have separate definitions of the level of evidence. This categorization, used for consensus statements, must not be considered as directly

Table 1 Scientific rationale of consensus statements

<table>
<thead>
<tr>
<th>Definitions related to a treatment or procedure</th>
<th>Consensus statement instruction</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific evidence that a treatment or procedure is beneficial and effective. Requires at least one randomized trial, or is supported by strong observational evidence and authors’ consensus.</td>
<td>‘Should do this’</td>
<td>🔺</td>
</tr>
<tr>
<td>General agreement and/or scientific evidence favour the usefulness / efficacy of a treatment or procedure. May be supported by randomized trials based on a small number of patients or which is not widely applicable.</td>
<td>‘May do this’</td>
<td>🔺</td>
</tr>
<tr>
<td>Scientific evidence or general agreement not to use or recommend a treatment or procedure.</td>
<td>‘Do not do this’</td>
<td>🔺</td>
</tr>
</tbody>
</table>

*This categorization for our consensus document should not be considered as being directly similar to that used for official society guideline recommendations.
similar to that used for official society guideline recommendations, which apply a classification (classes I–III) and level of evidence (A, B and C) to recommendations.

Thus, a green heart indicates a ‘should do this’ consensus statement or indicated treatment or procedure that is based on at least one RCT, or is supported by strong observational evidence that it is beneficial and effective. A yellow heart indicates general agreement and/or scientific evidence favouring a ‘may do this’ statement or the usefulness/effectiveness of a treatment or procedure. A yellow heart’ symbol may be supported by RCTs based on a small number of patients or which is not widely applicable. Treatment strategies for which there is scientific evidence of potential harm and should not be used (‘do not do this’) are indicated by a red heart.

**Epidemiology of Valvular AF and Implications for Stroke/Thromboembolism**

Robust data on the epidemiology of patients with AF and associated VHD are limited. Examples of available data from some global registries and large trials are reported in [Supplementary Table S1](online only). In the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) AF registry which enrolled patients presenting to an emergency department with AF at 164 sites in 46 countries, rheumatic heart disease was present in 2.2% of North American patients, 21.5% of African patients and 31.5% of Indian patients. TE rates were related to clinical risk profile, as expressed by CHADS2 score, irrespective of the presence of rheumatic VHD. Detailed data on the geographic distribution of valvular AF are also reported in the [Supplementary Tables S2](online only) and S3 (online only).

**Pathophysiology: A Brief Overview**

The drivers of thrombogenesis in AF include the elements of the Virchow’s triad: blood flow alterations, endocardial injury and changes in blood constituents. In fact, according to the recently published EHRA/HRS/APHRS/SOLACE consensus document, atrial tissue in VHD is characterized, at a histopathological level, by a combination of cardiomyocyte and fibrotic changes. An overview of the pathophysiology of thrombogenesis in AF in haemodynamically significant MS and/or mechanical heart valves prostheses is shown in [Fig. 1](online only).

The risk of TE is increased in patients with AF and mechanical valve, mild-to-severe MS and left atrium dilatation, compared with non-valvular AF, suggesting differences among the pathogenic mechanisms contributing to thrombosis in each of these AF conditions. It is generally thought that Virchow’s triad is triggered by the turbulent flow and the endothelial injury that accompanies valvular AF. On top of this, AF prosthetic valves (particularly mechanical prostheses) induce thrombin generation through the activation of both the tissue factor (TF) and the contact coagulation pathways. Surgical heart valve replacement surgery induces tissue damage with TF release leading to extrinsic coagulation pathway activation after binding to plasma factor (F) VII/FVIIa. Moreover, the exposure of valve leaflets, struts and/or sewing ring to the circulating blood can activate the contact (intrinsic) coagulation pathway. Both intrinsic and extrinsic pathways converge at the FX activation and then the transformation of prothrombin into thrombin (FIIa) and formation of the fibrin mesh. The vitamin K antagonist (VKA), warfarin, by blocking the formation of the vitamin K–dependent clotting FVII, FIX, FX and FII, prevents the activation of the coagulation cascade at the extrinsic and intrinsic pathway levels.

In addition to the thrombogenic contribution of plasma coagulation in valvular AF, platelet activation may possibly contribute particularly to the mild-to-severe MS. Finally, acquired type IIA von Willebrand disease and bleeding complications can be associated with severe aortic stenosis (AS) due to high-molecular-weight multimer consumption.

**Oral Anticoagulation with VKA in Patients with AF and Prosthetic Heart Valves, Including Bioprostheses**

**Mechanical Heart Valves**

Oral anticoagulation with VKA is crucial for the prevention of TE in patients with mechanical heart valves, regardless of the presence or absence of AF. The ESC guidelines establish the risk of TE in patients with mechanical valves according to valve type and position, and also according to the individual patient risk profile or comorbidities. Warfarin and other VKA are the most widely used OACs, and are titrated according to international normalized ratio (INR) range and target value which is also related with associated risk factors (Table 2). The duration of antithrombotic therapy also varies according to several factors. Lifelong anticoagulant treatment is indicated with a class I recommendation for all patients with mechanical valves, and for those with bioprosthetic valves or native valve disease with ≥2 additional stroke risk factors.

**Bioprostheses**

Patients with bioprostheses and additional risk factors for systemic TE (AF, venous thrombosis, hypercoagulable state, or with a lesser degree of evidence, severely impaired left ventricular function) require lifelong OAC. The use of NOACs instead of warfarin in this setting is accepted by the more recent document of recommendations by EHRA despite of a lack of RCTs.

After biological valve replacement, thromboembolic risk is estimated between 0.6 and 3.3% per year without anticoagulation, after the third month. The thromboembolic risk associated with a bioprosthesis and sinus rhythm is higher in the first 3 months after the surgery, the risk being almost eliminated in anticoagulated patients for aortic bioprosthesis, but remaining higher in patients with a mitral bioprosthesis. The benefit of an initial anticoagulant treatment following aortic valve replacement with a bioprosthesis and no AF is, however, debated.

Overall, AF patients with a bioprosthesis had a non-significantly higher risk of stroke/TE events compared with patients with non-valvular AF, and VKA use was independently associated with a lower risk of thromboembolic events (hazard ratio: 0.83, 95% confidence interval [CI]: 0.71–0.98). One small pilot study compared dabigatran versus warfarin after bioprosthesis valve replacement for the management of AF.
postoperatively (DAWA pilot study), but small numbers preclude definitive conclusions.32 Recent small studies also suggest that NOACs can be a reasonable alternative to VKA in patients with AF and remote bioprosthetic valve implantation;22,33 however, larger studies are needed to define the safety and efficacy profile. Data on thromboprophylaxis in patients with AF and TAVI, which is actually the insertion of a bioprosthesis, is preliminary34 and discussed in section ‘Antithrombotic Therapy in Patients with AF Undergoing TAVI or Left Atrial Appendage Occlusion’.

Table 2 Target INR for mechanical prosthesis (some examples)

<table>
<thead>
<tr>
<th>Prosthesis thrombogenicity</th>
<th>Valve type</th>
<th>Patient-related risk factorsa (risk factor ≥ 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>Carbomedics, Medtronic Hall, St Jude Medical, ON-X</td>
<td>3.0</td>
</tr>
<tr>
<td>Medium</td>
<td>Other bileaflet valves</td>
<td>3.5</td>
</tr>
<tr>
<td>High</td>
<td>Lillehei-Kaster, Omnicience, Starr-Edwards, Bjork-Shiley and other tilting-disc valves</td>
<td>4.0</td>
</tr>
</tbody>
</table>

*Risk factors: previous thromboembolism, atrial fibrillation, mitral stenosis of any degree, left ventricular ejection fraction <35%.

Source: Reproduced from Vahanian et al.20

Fig. 1 Pathophysiology of thrombogenesis in atrial fibrillation (AF)-related prosthesis and/or mitral valve diseases. In valvular AF, there is a propensity to thrombosis because of the presence of the Virchow’s triad components which, in turn, are found to be likely boosted by patients’ comorbid conditions. The risk of thrombosis, however, is enhanced because of the presence of prosthetic valves which activate the coagulation cascade (both the intrinsic and extrinsic pathway) leading to thrombin production (a strong platelet agonist) and, although to a lesser extent, because of the considerable degree of mitral stenosis which induces flow turbulences capable of inducing platelet activation. Finally, AF also frequently occurs in patients with severe aortic stenosis, which can be associated with the Heyde syndrome due to von Willebrand factor (VWF) consumption leading to an acquired bleeding disorder.
Mitral Valve Repair

Patients undergoing mitral valve repair have a small risk of TE,\textsuperscript{35} with the highest risk of TE occurring during the first year after surgery. Guidelines therefore recommend OAC during the first 3 to 6 months after the surgery.\textsuperscript{36} Only limited data are available on the efficacy of warfarin therapy in the early stages after valve surgery, and the use of short-term VKAs in patients with mitral valve annuloplasty is also controversial. It is therefore not clear whether patients with AF in addition to valve repair are markedly different from the patients with AF in the absence of VHD.\textsuperscript{4,16}

North American and European guidelines have a different position on this issue: the former considering AF in association with valve repair as ‘valvular AF’, while ESC guidelines do not do so.\textsuperscript{28,37}

Consensus statements:

<table>
<thead>
<tr>
<th>• Well-managed VKA monotherapy with good anticoagulation control (e.g. time in therapeutic range &gt;65–70%) is generally recommended, taking into account the type of valve, the position and additional risk factor(s), including atrial fibrillation.</th>
<th>Coloured heart</th>
<th>Supporting references</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>26</td>
</tr>
<tr>
<td>• Patients with a bioprosthetic valve and atrial fibrillation require lifelong OAC.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Indications of ‘Add-on’ Antiplatelet Therapy in Patients with AF and Prosthetic Mechanical Heart Valves

Arterial TE and valve thrombosis are approximately 12%/year and 22%/year, for mechanical valve prosthesis in the aortic and mitral position, respectively, in patients without VKA prophylaxis.\textsuperscript{25} The residual risk ranges from 0.5%/year to 2.5%/year\textsuperscript{25,38–40} in VKA-treated patients without additional cardiovascular risk factors such as AF. A higher incidence is associated with the mitral (~2%/year) versus the aortic (~1%/year) position, depending also on the type of valve and VKA intensity.\textsuperscript{25,39,40} AF and/or other risk factors (e.g. heart failure, even without AF) increase TE risk by fourfold, from 4 up to 8%/year,\textsuperscript{32,41,42} even on adequate VKA treatment.\textsuperscript{41,42}

Given this high-residual TE risk, RCTs have compared VKA alone versus VKA combined with different aspirin doses and/or dipyridamole\textsuperscript{25,43,44} (\textit{Table 3}).

Despite major methodological limitations of these studies including small sample size, heterogeneities in thrombotic risk level at study entry and anticoagulation intensity, as well as inconsistencies in safety and efficacy endpoint definitions,\textsuperscript{43} there may possibly be some benefit of adding low-dose aspirin (between 75 and 200 mg daily) to VKA in patients with mechanical valve prosthesis and additional risk factors including AF\textsuperscript{25,43,45} (\textit{Table 3}). This approach lowered TE complications in the majority of studies,\textsuperscript{25,41–43,46} and two meta-analyses showed approximately 60% relative risk reduction (RRR) of TE and approximately 50% RRR of all-cause mortality\textsuperscript{43,44} (\textit{Table 3}). Nonetheless, the relative risk of major bleeding with VKAs plus antiplatelet therapy increases by approximately 58% across studies including aspirin daily doses from 100 to 1,000 mg\textsuperscript{13,44} and high-dose dipyridamole alone or with aspirin.\textsuperscript{43} Importantly, major bleeding appears significantly affected by aspirin dose: the association with low dose (100 mg) shows a bleeding risk significantly lower than higher doses\textsuperscript{43,47} and not significantly different from VKA alone (odds ratio [OR] = 0.96; 95% confidence interval [CI]: 0.60–1.55; 2.58; 95% CI: 1.43–2.55 for low and high doses versus VKA, respectively, \( p = 0.002 \) for the high-dose aspirin combination versus VKA) with similar efficacy (\textit{Table 3}).\textsuperscript{43,47} Thus, VKA plus low-dose aspirin (75–100 mg daily) for the association of mechanical prosthetic valve and AF is recommended by the AHA/ASA/ACCP as a class I (level A or B) recommendation,\textsuperscript{38,40,48,49} but as a class IIb C recommendation by the ESC.

When the aspirin/VKA combination is used, anticoagulation should be titrated taking into account the type of valve, the position and comorbidities. The target INR for AF patients with aortic mechanical prosthetic valve on VKA and low-dose aspirin should be 2.5 (range: 2.0–3.0), with close attention to the quality of anticoagulation control, with time in therapeutic range (TTR) >65 to 70%.

Whether the INR target should be 2.5 (range: 2–3) or 3 (range: 2.5–3.5) in AF patients with mitral prosthetic valve on both VKA and low-dose aspirin is less clear. High-intensity VKA (i.e. INR range: 3–4 or higher), combined with aspirin, has been consistently associated with higher major bleeding and comparable benefit as lower intensity VKA with aspirin.\textsuperscript{50–52}

Consensus statements:

<table>
<thead>
<tr>
<th>• In patients with a mechanical prosthetic valve and concomitant AF with vascular disease, VKA plus low-dose aspirin (75–100 mg daily) may be considered in the absence of high bleeding risk.</th>
<th>Coloured heart</th>
<th>Supporting references</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>38,43,45–47,49,52</td>
</tr>
<tr>
<td>• In patients with a mechanical prosthetic valve and AF, when VKA plus aspirin is used, the INR should be kept between 2.0 and 3.0 (target 2.5), given the high bleeding risk of the combination and the lack of evidence of greater protection with higher intensity VKA (INR range: 3–5 or above).</td>
<td></td>
<td>49–51</td>
</tr>
<tr>
<td>• High doses of aspirin (≥325 mg) in association with VKA at any intensity must be avoided.</td>
<td></td>
<td>43,47,52</td>
</tr>
<tr>
<td>Reference</td>
<td>Design</td>
<td>Patients</td>
</tr>
<tr>
<td>-----------</td>
<td>--------</td>
<td>----------</td>
</tr>
<tr>
<td>Turpie et al&lt;sup&gt;41&lt;/sup&gt;</td>
<td>RCT: VKA (INR target: 3–4.5) + ASA 100 mg daily vs. VKA (INR target: 3–4.5) + placebo mean f.u.: 2.5 y</td>
<td>370 patients with MVR or tissue valve replacement + AF or TE; mean age 58 y males 50%</td>
</tr>
<tr>
<td>Altman et al&lt;sup&gt;47&lt;/sup&gt;</td>
<td>RCT: VKA (INR target: 2–3) + ASA 100 mg or ASA 650 mg daily mean f.u.: 20 mo</td>
<td>416 patients with mechanical MVR; mean age 60 y males 50%</td>
</tr>
<tr>
<td>Meschengieser et al&lt;sup&gt;51&lt;/sup&gt;</td>
<td>RCT: high-intensity VKA (INR: 3.5–4.5) vs. less intense VKA (INR: 2.5–3.5) + ASA 100 mg median f.u.: 23 mo</td>
<td>503 patients with MRV; ~30% mitral MVR median age 53 y males 58%</td>
</tr>
<tr>
<td>Laffort et al&lt;sup&gt;42&lt;/sup&gt;</td>
<td>RCT: VKA + ASA 200 mg daily vs. VKA alone INR target: 3 (2.5–3.5) f.u.: 1 y</td>
<td>229 patients with MVR; mean age 63 y males 50%</td>
</tr>
<tr>
<td>Larson and Fisher&lt;sup&gt;44&lt;/sup&gt;</td>
<td>Meta-analysis of 4 trials using aspirin</td>
<td>869 patients</td>
</tr>
</tbody>
</table>

(Continued)
Table 3 (Continued)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Design</th>
<th>Patients</th>
<th>AF and MVR position (%)</th>
<th>Efficacy</th>
<th>Safety</th>
<th>Comments or additional data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pengo et al (^{50})</td>
<td>RCT: low-intensity VKA (INR: 2–3) + ASA 100 mg vs. higher intensity VKA (INR: 2.5–3.5) for 6 mo f.u.: 1.5 y</td>
<td>198 patients with MVR; mean age 60 y males 46%</td>
<td>~28% per arm Mitral 28% Aortic 63% Multiple ~10%</td>
<td>VKA + ASA: 4 major bleeding and 1 ischemic stroke; VKA: 2 major bleeding and 2 ischemic stroke, ( p = 0.6 )</td>
<td>Cumulative endpoint of major bleeding and thrombosis</td>
<td>Very small study with short treatment and low number of events</td>
</tr>
<tr>
<td>Dong et al (^{46})</td>
<td>RCT: VKA + ASA 75–100 mg vs. VKA alone mean f.u.: 24 ± 9 mo</td>
<td>1,496 patients with mechanical MVR; mean age 35 y males 40%</td>
<td>AF: 40% per arm Mitral: 83% Aortic: 43% Multiple: 16%</td>
<td>Major TE: 2.1% VKA + ASA vs. 3.6% VKA alone, ( p = 0.04 ) NNT = 66</td>
<td>Major bleeding: 3.5 VKA + ASA vs. 3.7% in VKA alone; ( p = \text{n.s.} ) NNH = 500</td>
<td>Warfarin dose: 2.92 ± 0.87 mg in VKA + ASA and 2.89 ± 0.79 mg in VKA alone. No differences in mortality rate</td>
</tr>
<tr>
<td>Massel and Little (^{43})</td>
<td>Meta-analysis of RCT comparing VKA alone vs. VKA and antiplatelets</td>
<td>4,122 patients with MVR in aortic or mitral position or both</td>
<td>Variable depending on the study</td>
<td>Major TE: ASA + VKA vs. VKA alone; OR: 0.43 [95% CI: 0.32–0.5], ( p &lt; 0.001 )</td>
<td>Major bleeding: antiplatelet + VKA vs. VKA alone; OR: 1.58 [95% CI: 1.14–2.18], ( p &lt; 0.001 ) ASA high: OR, 2.58 [95% CI: 1.43–1.55] ASA 100 mg: OR, 0.96 [95% CI: 0.6–1.55] Statistical interaction high vs. low, ( p = 0.04 )</td>
<td>Overall mortality: OR, 0.57 [95% CI: 0.42–0.78] Major bleeding in studies pre-1990: OR, 2.34 [95% CI: 1.34–4.08] after-1990: OR, 1.26 [95% CI: 0.84–1.89]</td>
</tr>
</tbody>
</table>

Abbreviations: AF, atrial fibrillation; ASA, aspirin; CI, confidence interval; f.u., follow-up; INR, international normalized ratio; MVR, mechanical valve replacement; NNH, number needed to harm; NNT, number needed to treat; n.s., not significant; OR, odds ratio; RCT, randomized clinical trial; RRR, relative risk reduction; TE, thromboembolism; VKA, vitamin K antagonists.

Notes: Data are presented as %/y, whenever possible. NNT and NNH per year are calculated for the comparisons including the combined VKA + antiplatelet treatment versus VKA alone, whenever possible.
Evidence for NOACs Use in Patients with AF and VHD

Subgroups from the Recent NOAC Trials

The efficacy and safety of NOACs for the prevention of stroke/systemic embolic events (SSEE) in patients with non-valvular AF has been established by the pivotal RCTs. These trials excluded patients with significant MS or prosthetic mechanical valves but enrolled participants (13–26%, depending on the trial) with other clinically significant non-rheumatic VHD, including MR, aortic regurgitation (AR), AS, mild MS or prior valve surgery (bioprosthetic valves or valve repair) (Table 4). There are limited or no data on other options, such as MitraClip or other TMVI, and thus NOACs should not be used in these patients.

Variable inclusion/exclusion criteria across the NOACs trials reflect the prevailing lack of a clear-cut definition of valvular AF. Patients with VHD of non-rheumatic origin are prevalent in clinical practice, and physicians may often deny NOACs to eligible AF patients due to uncertainty over whether the patient has valvular or non-valvular AF.

There are no RCTs on NOACs in AF patients with VHD. In the RE-LY, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ROCKET-AF), Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) and Effective Anticoagulation with factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial subgroup analyses, non-valvular AF patients with VHD were older, had more comorbidities (including renal dysfunction), more persistent/permanent AF and higher cardio-embolic and bleeding risks than patients without VHD. While the use of aspirin was similarly common, prior VKA use was more common among patients with VHD. Irrespective of the treatment arm (i.e. warfarin or a NOAC), VHD patients generally experienced worse outcomes (stroke and systemic TE, major bleeding or all-cause death) in comparison to non-VHD patients (Table 5).

These trials demonstrate that NOACs are more effective and have a more favorable bleeding profile compared with VKA in AF patients with moderate-to-severe MS; as

| Table 4 | Inclusion/exclusion criteria pertinent to valvular heart disease in the pivotal NOAC trials in patients with ‘non-valvular’ AF and valvular disease–type distribution across the trials |
|-----------------------------------------------|------------------|------------------|------------------|------------------|------------------|
| Inclusion (✓)/exclusion (–) criteria          | RE-LY            | ROCKET-AF        | ARISTOTLE        | ENGAGE-AF        | AVERROES         |
| Prosthetic heart valve(s)                     |                  |                  |                  |                  |                  |
| • Mechanical                                  | –                | –                | –                | –                | –                |
| • Bioprosthesis                               | –                | –                | ✓                | ✓                | ✓                |
| Prior surgical repaira                        | –                | ✓                | ✓                | ✓                | ✓                |
| Moderate-to-severe MS                         | –                | –                | –                | –                | –                |
| Other significant valve diseaseb              | –                | ✓                | ✓                | ✓                | –                |
| Mild-to-moderate valve disease                | ✓                | ✓                | ✓                | ✓                | ✓                |
| Subgroups with a cardiac valve diseasec       | RE-LY            | ROCKET-AF        | ARISTOTLE        | ENGAGE-AF        |                  |
| Total number (%)                              | 3,950 (21.8)     | 2,003 (14.1)     | 4,808 (26.4)     | 2,824 (13.4)     |                  |
| Moderate/severe MR                            | 3,101 (78.5)     | 1,756 (87.7)     | 3,526 (73.3)     | 2,250 (79.6)     |                  |
| Moderate/severe AR                            | 817 (20.7)       | 486 (24.3)       | 887 (18.4)       | 369 (13.0)       |                  |
| Moderate/severe AS                            | 471 (11.9)       | 215 (10.7)       | 384 (8.0)        | 165 (5.8)        |                  |
| Other                                         | 1,179 (6.5)      | 11 (0.6)         | 2,124 (44.2)     | NR               |                  |
| Mild MS                                       | 193 (4.9)        | NR               | 131 (2.7)        | 254 (9.0)        |                  |
| Prior valve surgery (excluding mechanical prosthetic heart valve) | Not applicable | 106 (5.3) | 251 (5.2) | 325 (11.5) |                  |
| Valve repair                                  | –                | 42 (2.1%)        | NR               | 123 (4.3)        | NR               |
| Valvuloplasty                                 | –                | 64 (3.2%)        | NR               | 19 (0.7)         | NR               |
| Bioprosthetic valves                          | –                | Not applicable   | 82 (1.7)         | 191 (6.8)        | NR               |

Abbreviations: AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; MR, mitral regurgitation; MS, mitral stenosis; NOAC, non–vitamin K antagonist oral anticoagulant; NR, not reported.

aAnnuloplasty, commissurotomy, valvuloplasty, etc.
bClinically significant, but not requiring immediate surgery repair.
cCategories are not mutually exclusive.
dWithout any of the preceding.
Table 5

<table>
<thead>
<tr>
<th>Outcome trial</th>
<th>NOAC/ Warfarin</th>
<th>VTE (rate %/y)</th>
<th>Non-VTE (rate %/y)</th>
<th>VTE NOAC vs. warfarin</th>
<th>Non-VTE NOAC vs. warfarin</th>
<th>Interaction p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>VHD (rate %/y)</td>
<td>Non-VHD (rate %/y)</td>
<td>HR (95% CI)</td>
<td>HR (95% CI)</td>
<td>p</td>
</tr>
<tr>
<td>Stroke/SE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROCK-ACH</td>
<td>Rivaroxaban/Warfarin</td>
<td>2.01/2.43</td>
<td>1.96/2.22</td>
<td>0.83 (0.55–1.27)</td>
<td>0.89 (0.75–1.07)</td>
<td>0.70</td>
</tr>
<tr>
<td>ARISTOTE</td>
<td>Apixaban/Warfarin</td>
<td>1.46/2.08</td>
<td>1.20/1.43</td>
<td>0.70 (0.51–0.97)</td>
<td>0.84 (0.67–1.04)</td>
<td>0.378</td>
</tr>
<tr>
<td>RE-LV</td>
<td>Dabi-150 mg/Warfarin</td>
<td>1.12/1.90</td>
<td>1.11/1.66</td>
<td>0.59 (0.37–0.93)</td>
<td>0.67 (0.52–0.86)</td>
<td>0.63</td>
</tr>
<tr>
<td>ENGAGE-A</td>
<td>HDER/Warfarin</td>
<td>1.94/2.02</td>
<td>1.60/1.77</td>
<td>0.69 (0.44–1.07)</td>
<td>0.91 (0.77–1.07)</td>
<td>0.255</td>
</tr>
<tr>
<td></td>
<td>LDER/Warfarin</td>
<td>1.84/1.90</td>
<td>1.45/1.66</td>
<td>0.97 (0.65–1.45)</td>
<td>1.15 (0.98–1.35)</td>
<td>0.440</td>
</tr>
<tr>
<td>Major bleeding</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROCK-ACH</td>
<td>Rivaroxaban/Warfarin</td>
<td>6.14/4.20</td>
<td>3.22/3.33</td>
<td>1.56 (1.14–2.14)</td>
<td>0.98 (0.84–1.15)</td>
<td>0.01</td>
</tr>
<tr>
<td>ARISTOTE</td>
<td>Apixaban/Warfarin</td>
<td>2.49/3.14</td>
<td>2.01/3.07</td>
<td>0.79 (0.61–1.04)</td>
<td>0.65 (0.55–0.77)</td>
<td>0.23</td>
</tr>
<tr>
<td>RE-LV</td>
<td>Dabi-150 mg/Warfarin</td>
<td>4.21/5.12</td>
<td>3.06/3.14</td>
<td>0.82 (0.64–1.06)</td>
<td>0.98 (0.83–1.15)</td>
<td>0.25</td>
</tr>
<tr>
<td></td>
<td>Dabi-110 mg/Warfarin</td>
<td>3.77/5.12</td>
<td>2.63/3.14</td>
<td>0.73 (0.56–0.95)</td>
<td>0.84 (0.71–0.99)</td>
<td>0.38</td>
</tr>
<tr>
<td>ENGAGE-A</td>
<td>HDER/Warfarin</td>
<td>2.78/3.46</td>
<td>1.82/3.37</td>
<td>0.74 (0.53–1.02)</td>
<td>0.82 (0.71–0.94)</td>
<td>0.573</td>
</tr>
<tr>
<td></td>
<td>LDER/Warfarin</td>
<td>2.95/3.27</td>
<td>2.04/3.17</td>
<td>0.41 (0.28–0.60)</td>
<td>0.49 (0.41–0.57)</td>
<td>0.439</td>
</tr>
<tr>
<td>Major death</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROCK-ACH</td>
<td>Rivaroxaban/Warfarin</td>
<td>0.88/0.73</td>
<td>0.43/0.74</td>
<td>1.27 (0.58–2.79)</td>
<td>0.59 (0.40–0.86)</td>
<td>0.084</td>
</tr>
<tr>
<td>ARISTOTE</td>
<td>Apixaban/Warfarin</td>
<td>0.25/0.88</td>
<td>0.37/0.78</td>
<td>0.28 (0.14–0.57)</td>
<td>0.47 (0.33–0.68)</td>
<td>0.20</td>
</tr>
<tr>
<td>RE-LV</td>
<td>Dabi-150 mg/Warfarin</td>
<td>0.34/0.93</td>
<td>0.31/0.72</td>
<td>0.36 (0.17–0.77)</td>
<td>0.43 (0.28–0.67)</td>
<td>0.68</td>
</tr>
<tr>
<td></td>
<td>Dabi-110 mg/Warfarin</td>
<td>0.27/0.93</td>
<td>0.21/0.72</td>
<td>0.29 (0.13–0.68)</td>
<td>0.30 (0.18–0.49)</td>
<td>0.98</td>
</tr>
<tr>
<td>ENGAGE-A</td>
<td>HDER/Warfarin</td>
<td>0.32/0.82</td>
<td>0.41/0.85</td>
<td>0.39 (0.15–0.98)</td>
<td>0.48 (0.35–0.66)</td>
<td>0.657</td>
</tr>
<tr>
<td></td>
<td>LDER/Warfarin</td>
<td>0.24/0.82</td>
<td>0.26/0.85</td>
<td>0.29 (0.11–0.79)</td>
<td>0.31 (0.21–0.45)</td>
<td>0.926</td>
</tr>
</tbody>
</table>

Abbreviations: HDER, higher dose edoxaban regimen; ICH, intracranial haemorrhage; LDER, lower dose edoxaban regimen; NA, not applicable; NOACS, non–vitamin K oral anticoagulants; NR, not reported; SE, systemic embolism; VHD, valvular heart disease.

Note: There was no effect of modification of the presence or absence of VHD on relative outcomes with HDER or LDER in comparison to warfarin (all interaction p were non-significant).

*In the sub-analyses including only bioprosthetic valves, the rates of ICH were not specified: composite outcome of stroke/SE, major bleeding or death.
mentioned earlier, these patients were not enrolled in the NOACs trials.

The number of patients with any prior valve surgery (i.e. bioprosthetic valves or valve repair) exposed to rivaroxaban, apixaban or edoxaban in the ROCKET-AF, ARISTOTLE or ENGAGE AF-TIMI 48 trials was very low (Table 4). Nevertheless, as reported for apixaban and edoxaban,22,23 there was no statistically significant interaction between the presence of a bioprosthetic heart valve and the respective NOAC effects (Table 5), thus suggesting that apixaban or edoxaban may possibly be alternatives to warfarin in AF patients with bioprosthetic valves implanted ≥3 months ago.

A meta-analysis of the VHD subgroups from the RE-LY, ROCKET-AF, ARISTOTLE and ENGAGE AF-TIMI 48 trials22 broadly confirmed the findings shown in Table 5. Overall, AF patients with VHD had non-significantly higher rate of SSEE (RR: 1.13; 95% CI: 0.99–1.28) and significantly higher rates of major bleeding (RR: 1.34; 95% CI: 1.13–1.49) and all-cause death (RR: 1.34; 95% CI: 1.13–1.59) than patients without VHD.

Compared with warfarin, the use of NOACs (i.e. rivaroxaban, apixaban or higher doses of dabigatran or edoxaban) was associated with consistently lower rates of SSEE regardless of the presence or absence of VHD (RR: 0.70; 95% CI: 0.58–0.86 and 0.84; 95% CI: 0.75–0.95, respectively; interaction p = 0.31), similar major bleeding rates (VHD RR: 0.93; 95% CI: 0.67–1.27 and non-VHD RR: 0.85; 95% CI: 0.70–1.02, interaction p = 0.63), consistently lower rates of ICH (VHD RR: 0.47; 95% CI: 0.24–0.93 and non-VHD RR: 0.49; 95% CI: 0.41–0.59, interaction p = 0.91) and higher all-cause death rate in VHD patients (RR 1.01; 95% CI, 0.90–1.14) than in those without VHD (RR 0.88; 95% CI, 0.82–0.94, interaction p = 0.03).63 In the analysis that also included the lower doses of dabigatran and edoxaban, the magnitude of SSEE risk reduction with NOACs versus warfarin was slightly reduced, as well as the rates of major bleeding and ICH, but there were no significant subgroup interactions by VHD status. Overall, the presence of VHD did not affect the relative protective effect of NOACs compared with warfarin in terms of SSEE and major bleeding. These findings were further supported by another meta-analysis of the four NOACs yielding identical results.64 Of note, both meta-analyses reported significant treatment effect heterogeneity regarding major bleeding in both the VHD and non-VHD analyses.

With the exclusion of patients with moderate-to-severe MS, prosthetic mechanical heart valve, TAVI or TMVI, who were not enrolled in the non-valvular AF trials, the aforementioned subgroup and meta-analyses may suggest that AF patients with VHD would experience at least the same benefit from NOACs as patients without VHD. However, due to limitations inherent to these types of analyses, further RCTs are required in AF patients with VHD before recommendations can be given (see Tables 4 and 5).

### Prosthetic Mechanical Heart Valves

Mechanical valve prostheses trigger complex mechanisms of thrombogenesis and are associated with a very high cardi-embolic risk requiring chronic OAC even in the absence of AF. Animal studies on mechanical valve implantation using first the direct FIIa inhibitors melagatran65 and then dabigatran66,67 as well as the phase III data from the RE-LY trial53 informed the only study to date on a NOAC in patients with mechanical heart valves.

The Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etxetilate in Patients after Heart Valve Replacement (RE-ALIGN) trial was a phase-II, controlled, dose-finding, open-label study68 randomizing (2:1) patients with aortic (n = 172; 68%) or mitral (n = 71; 28%) mechanical valve replacement, or both (n = 9; 4%) to dabigatran or adjusted-dose warfarin (target INR: 2.0–3.0 or 2.5–3.5 in aortic or mitral position, respectively). The initial dabigatran dose of 150, 220 or 300 mg twice daily (bid) (selected according to renal function) was further adjusted over 12 weeks to achieve the primary study outcome—a trough plasma concentration of ≥50 ng/mL, based on the pharmacokinetic model from the RE-LY trial. Most patients (79%) received study drug 5 to 7 days after the surgery, and 23% of patients had AF. The RE-ALIGN study was prematurely terminated after randomizing 252 of 405 planned patients, due to an excess in stroke (5 vs.0%), valve thrombosis (3 vs. 0%) and major bleeding events (4 vs. 2%) in the dabigatran arm, after a mean dabigatran exposure of ~20 weeks. Different explanations have been proposed, including inadequate dabigatran plasma concentrations, different pharmaco-dynamics of dabigatran and warfarin, excessive activation of the contact coagulation pathway induced by the sewing ring in the early postoperative course, a higher inter-individual variability in the dabigatran arm and differences in predicted versus observed drug concentrations in the RE-LY versus RE-ALIGN.68 A recent in vitro study suggested that the dabigatran trough plasma concentration required to reduce valve-induced FIIa generation should be much higher than 50 ng/mL (i.e. 260 ng/mL) corresponding to a 620-mg bid dosing.69 At present, all AF patients with a mechanical valve prosthesis should be treated with VKAs.

### Consensus statements:

<table>
<thead>
<tr>
<th>Coloured heart</th>
<th>Supporting references</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="heart.png" alt="Heart" /></td>
<td>-</td>
</tr>
</tbody>
</table>

- The use of the oral direct FIIa inhibitor dabigatran in patients with AF and mechanical valve prosthesis is contraindicated.

- Randomized clinical trials testing the efficacy and safety of direct oral FXa inhibitors in patients with AF and mechanical heart valve prosthesis are lacking. Until more data are available, rivaroxaban, apixaban and edoxaban are contraindicated in such patients.

(Continued)
Antithrombotic Therapy in Patients with AF Undergoing TAVI or Left Atrial Appendage Occlusion

Transaortic Valve Intervention Procedure

Most ischemic events after TAVI are cerebrovascular, and for these AF is a strong contributor. AF is common among high-risk patients with severe AS undergoing TAVI, and is associated with a more than twofold increased risk of all-cause and cardiovascular death, irrespective of the type of AF. In addition, the implanted valve adds a prothrombotic environment, which would accentuate the cardioembolic. Of importance, the gradient of risk directly correlates with the CHA2DS2-VASc score, which is usually used to aid decision making as whether to initiate OAC. A strategy that seems underused and that has never been evaluated prospectively. Dual antiplatelet therapy (DAPT) remains the most widely used antithrombotic strategy after TAVI, being used in >60% of patients, while VKA is used in <20% of patients, although AF is observed in >40% of TAVI patients. Current recommendations are expert driven, rather than evidence based (→Table 6).

Up to 35% of patients undergo coronary stenting prior to TAVI. In such patients, the risk of stent thrombosis and/or ischemic cardiac events in addition to that of AF should be considered in the overall risk assessment. Triple therapy, a combination of a VKA, low-dose aspirin and clopidogrel, which is used in high-risk patients, is associated with an increased risk of death, stroke, TE or major bleeding when compared with VKA alone. Such combinations should be discussed in the context of recent (i.e. < 6 months) acute coronary syndrome and/or stent implantation, especially in the presence of an unfavourable coronary anatomy (more than three stents, stent length ≥60 mm, multivessel disease, left main disease), but should be avoided whenever deemed possible given the established better safety and the possible preserved efficacy of a combination of warfarin and clopidogrel in patients with AF undergoing drug-eluting stent placement.

Recent evidence suggests that VKA alone is much safer and provides a similar rate of ischemic events as compared with VKA plus antiplatelet therapy (aspirin) in patients undergoing TAVI. However, this study was observational, not randomized with an unbalanced number of patients per treatment arm, and randomized confirmation is needed. Therefore, the association of OAC with single antiplatelet therapy in AF patients who underwent successful TAVI should be considered up to 1 year when there is a recent ACS or a recent coronary stenting and when the bleeding risk is deemed low (→Fig. 2).

OAC alone as antithrombotic strategy is currently being tested in three trials (POPular-TAVI NCT02247128, GALILEO NCT02556203, ATLANTIS trial NCT02664649), while another trial is testing aspirin alone or in combination with clopidogrel (ARTE NCT02640794), although AF patients appear excluded. Indeed, the benefit of VKA over DAPT in AF depends on the quality of INR control, and it has been modelled that a TTR >58% would be needed to benefit from being on OAC rather than on DAPT, which is probably not the case in the TAVI population.

Subclinical valve thrombosis is another challenging issue, as it may occur early after TAVI. Although the frequency of this potentially ominous phenomenon remains undefined, as this condition is difficult to detect, it seems reversible with anticoagulation. Whether it is associated with cerebrovascular events remains to be established. Given all these uncertainties, ongoing trials are also testing the anticoagulation hypothesis after successful TAVI irrespective of the need for OAC hypotheses using NOACs (NCT02556203, NCT02664649) which have been shown to be better tolerated. →Fig. 2 shows all currently recommended treatment options.

Recent observational evidence suggests the safety of FXa inhibition in TAVI, showing the feasibility of NOAC in the
Table 6 Recommendations for antithrombotic therapy during and after TAVI in the guidelines in patients with and without indication for OAC

<table>
<thead>
<tr>
<th>Procedural</th>
<th>ACC/AHA/STS91</th>
<th>ESC90</th>
<th>ACCP40</th>
<th>CCS40,92</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unfractionated heparin (ACT &gt; 300 s)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Post-procedural</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin 81 mg indefinitely and clopidogrel 75 mg for 3 up to 6 mo</td>
<td>Aspirin (or clopidogrel) indefinitely</td>
<td>Aspirin (50–100 mg/d) and clopidogrel (75 mg/d) in the first 3 mo</td>
<td>Low-dose aspirin indefinitely and 1–3 mo of a thienopyridine (no evidence)</td>
<td></td>
</tr>
<tr>
<td>Patients with a clear indication for OAC (as in AF)</td>
<td>It is reasonable to continue low-dose aspirin, but other antiplatelet therapy should be avoided</td>
<td>No antiplatelet therapy but OAC alone</td>
<td>No recommendation</td>
<td>Adjunctive antiplatelet agents are controversial and triple therapy should be avoided</td>
</tr>
</tbody>
</table>

Abbreviations: ACC, American College of Cardiology; ACT, activated clotting time; ACCP, American College of Chest Physicians; AF, atrial fibrillation; AHA, American Heart Association; ASA, acetylsalicylic acid (aspirin); AVR, aortic valve replacement; CCS, Canadian Cardiovascular Society; ESC, European Society of Cardiology; INR, international normalized ratio; OAC, oral anticoagulation; VKA, vitamin K antagonists.

Antithrombotic therapy following LAAO has not been well evaluated, and it is not even known whether OAC or antiplatelet therapy or no therapy is preferable. When possible, according to the patient bleeding risk profile, after LAAO most centres use a 6-week period of VKA (target INR: 2.5) followed by once daily (od) clopidogrel (75 mg) and aspirin (75–325 mg) until the 6-month visit. Some patients may also receive NOAC. Subsequently, low-dose aspirin alone is continued indefinitely, as tested in the pivotal trials. This antiplatelet regimen has never been compared with any long-term NOAC-based OAC regimen. However, the ASAP study showed that LAAO with the Watchman device has been increasingly developed and performed worldwide for patients with AF, especially those with contraindications to long-term OAC. This is supported by guidelines from the ESC, which give a class IIb recommendation for LAAO in AF patients with high stroke risk and contraindications to long-term OAC.2

Fig. 2 Proposed algorithm for AF patients undergoing a TAVI procedure. (Adapted Gargiulo et al130). O refers to oral anticoagulation as VKA (or possibly NOAC). ACS, acute coronary syndrome; AF, atrial fibrillation; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; OAC, NOAC, non–vitamin K antagonist oral anticoagulant; oral anticoagulant; SAPT, single antiplatelet therapy; TAVI, transaortic valve intervention; VKA, vitamin K antagonist.
is feasible and could be safely performed without OAC cover (but with antiplatelet therapy). Such strategy is being evaluated in the ongoing ADRIATIC study (Apixaban versus Dual or single antiplatelet therapy to Reduce Ischemic and bleeding events in Atrial fibrillation patients Treated with Invasive Closure of the left atrial appendage).

The ASAP TOO randomized trial (NCT02928497) is currently establishing the safety and effectiveness of the LAAO versus single antiplatelet therapy in patients with non-valvular AF deemed not to be eligible for OAC to reduce the risk of stroke.

Consensus statements:

<table>
<thead>
<tr>
<th>AF patients who underwent successful TAVI may be treated with NOACs; however, data are limited.</th>
<th>Coloured heart</th>
<th>Supporting references</th>
</tr>
</thead>
<tbody>
<tr>
<td>•</td>
<td></td>
<td>89</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>AF patients with stable coronary artery disease who underwent TAVI may be treated with OAC only, including VKA and FXa inhibitors; however, prospective data are limited.</th>
<th>Coloured heart</th>
<th>Supporting references</th>
</tr>
</thead>
<tbody>
<tr>
<td>•</td>
<td></td>
<td>74,89–92</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Based on trial protocols, OAC and single antiplatelet therapy after successful LAAO may be used up to 6 weeks in low bleeding risk patients, followed by single antiplatelet therapy; however, long-term data are limited, nor any comparison with NOACs.</th>
<th>Coloured heart</th>
<th>Supporting references</th>
</tr>
</thead>
<tbody>
<tr>
<td>•</td>
<td></td>
<td>81,82,86</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Single antiplatelet therapy or no antithrombotic therapy may be used after LAAO in AF patients who are not eligible for VKA; however, long-term data are limited, nor any comparison with NOACs.</th>
<th>Coloured heart</th>
<th>Supporting references</th>
</tr>
</thead>
<tbody>
<tr>
<td>•</td>
<td></td>
<td>87,88</td>
</tr>
</tbody>
</table>

Antithrombotic Therapy for Valvular AF in Pregnant Women

Valvular AF in pregnancy is relatively rare and can be due to congenital heart disease, mitral valve prolapse with significant MR, or to rheumatic heart disease. Valves can be repaired or replaced with a mechanical valve prosthesis. Pregnancy by itself is a prothrombotic state and the coalescence of venous stasis and hypercoagulability results in nearly a fivefold increase in the risk of venous TE during pregnancy. The goal of anticoagulation during pregnancy should be to safely balance the maternal risk of TE and haemorrhage with the foetal risk of exposure to VKA. The continuously changing pharmacokinetics of low-molecular-weight heparin during the various trimesters adds an additional challenge and requires monitoring by peak and trough anti-Xa levels, which is often not feasible (Fig. 3).

Women of child-bearing age with VHD need to be comprehensively counselled prior to valve replacement and pre-pregnancy to decide on the most appropriate type of valve and to be made aware of the teratogenicity and fetotoxicity of VKA, pregnancy-induced hemodynamic changes and the pre-existing hypercoagulable state which can compromise foetal development and significantly increase the risk of serious and/or fatal complications to both mother and child. Women with mechanical prosthetic valves should ideally have preconception evaluation, including advice on risk prediction and contraception, by a joint cardiobostetric team seeking advice from other specialties. Careful counselling on maternal and offspring risk should be done according to the modified World Health Organization classification and should include information on complications such as heart failure, valve thrombosis and bleeding complications which can occur during or beyond the immediate delivery period. Also, the consequences of the medication that may be required (e.g. warfarin embryopathy) need to be discussed. However, often women in some countries may present after 20 weeks of gestation, which has implications for their functional assessment, harmful medication cannot be terminated timely and limits the option for pregnancy termination.

Since anticoagulation is recommended in pregnant patients with AF at risk of stroke, to minimize teratogenic risk and intrauterine bleeding, the ESC guidelines recommend that dose-adjusted heparin should be used during the first trimester of pregnancy and in the 2 to 4 weeks before delivery. VKA or heparin can be used in the remaining trimesters of the pregnancy. In the absence of adequate safety data, NOACs should clearly be avoided in pregnancy and in women planning a pregnancy.

Consensus statements:

<table>
<thead>
<tr>
<th>There is no consensus on the optimal regimen for anticoagulation in peripartum women with mechanical valve prosthesis with AF.</th>
<th>Coloured heart</th>
<th>Supporting references</th>
</tr>
</thead>
<tbody>
<tr>
<td>•</td>
<td></td>
<td>93,94,96</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>As the optimal anticoagulation regimen for use in pregnancy and peripartum remains underdetermined, all decisions should be made by a fully informed mother and partner in consultation with a multidisciplinary team.</th>
<th>Coloured heart</th>
<th>Supporting references</th>
</tr>
</thead>
<tbody>
<tr>
<td>•</td>
<td></td>
<td>93,94,96</td>
</tr>
</tbody>
</table>
Patient Values and Preferences, and Societal Issues

Treatment decisions need to balance the benefits and risks of treatment and manage realistic patient expectations, particularly in association with comorbidities and in pregnancy. These decisions are complex and require assimilation of life expectancy, ability and willingness to take anticoagulants, risk of bleeding, lifestyle, comorbidities, risk of reoperation and patient preference.

Clinical guidelines on the management of VHD advocate incorporating informed patient preferences into treatment decisions and technological advances (for VHD) must be employed responsibly within a framework of care which enables shared decision making and promotes patient goals and well-being. This requires candid discussions between the patient and physician to ensure that treatment is not futile. Shared decision making requires patients to be appropriately informed about treatment options and likely outcomes, to have the type of patient–physician relationship where patients feel able to ask questions and where physicians provide information and communicate risk effectively, to enable patients to make an informed decision incorporating their values, goals and preferences. Patient's treatment preferences are likely to vary markedly, with patients often willing to accept higher levels of risk.

Implications for Low-to-Middle Income Countries

Valvular AF is more common in the Asian and African population compared with their western counterparts mainly due to greater burden of rheumatic heart disease. Stroke risk is higher among patients with valvular AF (17–18%/year) compared with those with non-valvular AF (4%/year). Furthermore, AF may further increase the risk of bioprosthetic valve thrombosis ([Supplementary Table S4](online only)). The burden of rheumatic valve disease is higher, but the quality of anticoagulation is suboptimal in low- and middle-income countries. Monitoring of the INR and follow-up remains poor and significant proportion of patients presents with subtherapeutic INR. The majority of these patients are young (median age: 28 years), unemployed (75.3%) and women (51–66%) of reproductive age. On average, they tend to be nearly 10 to 12 years younger than their western counterparts. Many are unaware of the concept of therapeutic range INR (60%) and few (< 4%) are on contraceptives despite treatment with warfarin. The NOACs are expensive and beyond the reach of the majority of patients requiring them in these countries. Suboptimal anticoagulation and consequent increased risk of stroke may lead to significant disability-adjusted life-years lost and this is likely to pose a major economic burden. Strategies to improve awareness about the disease, medication side effects, the importance of medication adherence and INR monitoring, and the danger of anticoagulation during pregnancy are scanty. Although point-of-care INR testing shows promise ([Supplementary Table S4](online only)),
its use among patients from the developing world needs to be determined. The impact of NOACs is less certain, although one recent Brazilian study evaluating NOACs in public health system context found that NOACs present a lower cumulative cost per patient when compared with VKAs.\textsuperscript{114}

**Health Economic Perspectives**

AF is a disease that induces significant consumption of resources and costs, encompassing direct medical costs, associated with patient’s medical care (hospitalizations, medications, outpatient visits, etc.), and direct non-medical costs (i.e. costs related to residential or social care, as well as out-of-pocket expenses).\textsuperscript{115,116}

Other costs that are usually taken into account in health-economic analyses are productivity losses caused by patients’ inability to work, or absence from work of relatives providing informal care.\textsuperscript{119} In patients with AF, direct costs, reported as per-patient annual costs, have been estimated to be $2,000 to 14,200 in North America and 450 to 3,000 Euros in Europe per patient.\textsuperscript{117}

Patients with VHD who have AF require appropriate risk stratification for stroke/SE and, when indicated, the consequent prescription of OAC implies a difficult balance between the risk of stroke and systemic TE and the risk of bleeding.\textsuperscript{118,119} Stroke and major bleeding have also an economic effect. Indeed, the main drivers of costs in AF patients are AF-related hospitalizations, stroke and haemorrhagic events. For strokes occurring in patients with AF, the direct costs per patient are approximately 33% greater than the costs of stroke not related to AF\textsuperscript{120} and are in the range of 30,000 Euros over a 2-year period for a severe ischemic stroke.\textsuperscript{121} The costs of intracerebral haemorrhage is 50% higher than the cost of ischemic stroke over a 1-year time course.\textsuperscript{122}

Underutilization of, and non-adherence to, warfarin is also quite common and is associated with increased costs,\textsuperscript{123,124} resulting from TE and haemorrhagic complications. Improved adherence to OAC in AF patients at risk of stroke is important to attain the full clinical and economic benefit of thromboprophylaxis.

NOACs can be prescribed to some subgroups of patients with VHD,\textsuperscript{125,126} and a series of analyses focusing on the cost-effectiveness of these agents versus warfarin has been published, although no study considered patients with VHD separately. In general, despite the higher cost of NOACs as compared with warfarin, the associated benefits make these agents cost-effective in the long term, especially in settings with poor anticoagulation control associated with VKAs.\textsuperscript{127,128}

**Summary and Areas for Future Research**

**Mechanical Valve Prostheses**

Currently, patients with AF and a mechanical prosthesis should only be treated with a VKA. Since the RE-ALIGN study, no other NOAC (FXa inhibitor drug class) has been tested in this patient group.\textsuperscript{58} However, the thrombotic risk could be reduced once endothelial tissue is present around the ring.\textsuperscript{12} A RCT could potentially be designed after endothelialization: the first 3 months with VKA, followed by a randomized comparison between continuing VKA or switching to a NOAC.

One trial proposed or ongoing with NOACs in patients with and without AF is the CATHAR trial (Comparison of Antithrombotic Treatments after Aortic Valve Replacement; Rivaroxaban: A New Antithrombotic Treatment for Patients with Mechanical Prosthetic Aortic Heart Valve: https://clinicaltrials.gov/ct2/show/NCT02128841?term=rivaroxaban+and+mechanical+valve&rank=2).

**Bioprostheses, TAVI and TMVI**

Usually, patients with a bioprosthesis and AF receive a VKA. Pericardial valves are less thrombogenic than mechanical valve prostheses. Some physicians do not consider bioprostheses as a contra-indication of NOACs. Before recommending a NOAC rather than VKA for these patients, a RCT is needed. This is also the case for patients undergoing valve repair.

TAVI corresponds to transluminal implantation of a bioprosthesis and is increasingly used. The antithrombotic treatment in patients with sinus rhythm and TAVI remains controversial and the optimal treatment in patients with AF requiring TAVI (as well as TMVI—see earlier section) is currently unknown.

A global study comparing a rivaroxaban-based antithrombotic strategy to an antiplatelet-based strategy after TAVI to optimize clinical outcomes (GALLILEO) is ongoing.\textsuperscript{129,130} The two arms consist of either rivaroxaban 10 mg od plus aspirin 75 to 100 mg for the first 90 days, followed by rivaroxaban alone; or clopidogrel 75 mg plus aspirin 75 to 100 mg for the first 90 days, followed by clopidogrel alone. Patients with current or previous AF are excluded. The investigators assume that 15% of patients in sinus rhythm at inclusion will develop AF during follow-up. Treatment after new-onset AF will be, in patients randomized to rivaroxaban, a switch to rivaroxaban 20 or 15 mg od for those with moderate renal impairment and in those randomized to clopidogrel, a switch to VKA (target INR: 2–3).

Another ongoing study is the Anti-Thrombotic Strategy after Trans-Aortic Valve Implantation for Aortic Stenosis (ATLANTIS) study which is ongoing and plans to include 1,509 patients after successful TAVI procedure. Randomization will be stratified according to the need for oral anticoagulant. Patients with an indication for OAC will be randomized 1:1 to VKA or apixaban 5 mg bid. The primary endpoint after 1 year follow-up is a composite of death, myocardial infarction, stroke, systemic embolization, intracardiac or bioprosthesis thrombus, episode of deep vein thrombosis or pulmonary embolism, and major bleeding. Patients with no indication for oral anticoagulant therapy will be randomized 1:1 to either apixaban 5 mg bid or

*Consensus statements:*

<table>
<thead>
<tr>
<th>Coloured heart</th>
<th>Supporting references</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Appropriate use of oral anticoagulants, when clinically indicated, has both a clinical and economic value, as underutilization and/or non-adherence are associated with adverse outcomes and increased costs.</td>
<td>119–121</td>
</tr>
</tbody>
</table>
antiplatelet therapy. Other trials are also proposed or ongoing with NOACs in patients with and without AF, including the RIVER Trial (Rivaroxaban for bioprosthetic Valvular Heart disease) and arterial Fibrillation Trial; warfarin vs. rivaroxaban).

**Native Valve Diseases**

The main phase III studies of NOACs have used variable criteria for excluding valvular patients. Some studies (ROCKET-AF and ARISTOTLE) excluded only patients with mechanical valve prostheses and significant (moderate to severe) MS. The sub-analyses did not show any differences in efficacy among patients with and without VHD. In the ROCKET-AF, there was more bleeding on rivaroxaban than on VKA in patients with VHD.

A report from the Loire Valley Atrial Fibrillation Project compared the outcome of patients without any valve disease and those with valve disease but did not include either valve prosthesis or MS. Although patients with VHD had a higher risk of stroke and TE events on univariable analysis, the difference was no longer significant after adjustment, in line with an older age and a higher CHA2DS2-VASC score in patients with VHD.1,26

However, post hoc analyses are only hypothesis generating. Large RCTs are needed with NOACs in the setting of AS, non-rheumatic AR and MR before the role of NOACs can be fully defined in this setting.

**Mitral Stenosis**

There has not yet been a RCT comparing VKA and NOACs in these patients. The prevalence of rheumatic MS has become low in Western countries but remains high in Eastern Europe, India, Africa, South America and South East Asia. In these regions, the TTR is only 35 to 44%, according to a global AF registry.5 RCTs comparing VKA with a NOAC are highly welcomed and should preferably include patients from these affected countries.

**Acknowledgements**

This article is an Executive Summary of the full consensus document which has been published as Lip et al Europace 2017; 19, 1757–1758

**Document Reviewers**

Bulent Gorenek (reviewer coordinator): Eskisehir Osmangazi University, Eskisehir, Turkey

Irina Savelieva: Molecular and Clinical Sciences Institute, St George’s University of London, London, United Kingdom

Christian Sticherling: Department of Cardiology, University Hospital Basel, Basel, Switzerland

Gulmira Kudaiberdieva: Adana, Turkey

Tze-Fan Chao (APHRS reviewer): Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, and Institute of Clinical Medicine, Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan

Francesco Violi: University of Rome La Sapienza, Rome, Italy

Mohan Nair: Department of Cardiology, Department of Medicine, Aalborg University, Aalborg, Denmark

Robert Storey: Department of Cardiovascular Sciences, University of Sheffield, Sheffield, United Kingdom

Sigrun Halvorsen: National Heart and Lung Institute, Imperial College, London, and Postgraduate Medicine, University of Hertfordshire, Hertfordshire, United Kingdom

Diana Gorog: Department of Cardiology, Oslo University Hospital, Ulleval, Oslo, Norway

Andrea Rubboli (Working Group of Thrombosis reviewer): Ospedale Maggiore – Division of Cardiology, Bologna, Italy

Ashley Chin (CASSA reviewer): Electrophysiology and Pacing, Groote Schuur Hospital, University of Cape Town, South Africa

Robert Scott-Millar (SAHeart reviewer): Division of Cardiology, Department of Medicine, Cape Town, South Africa

Jonathan Piccini (HRS reviewer): Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, United States

**From EHRA:**

| Gregory Y. H. Lip (Chair) (UK, representing EHRA) | Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom; and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark |
| Laurent Fauchier | Centre Hospitalier Universitaire Trousseau et Faculté de Médecine – Université François Rabelais, Tours, France |
| Raffaele De Caterina | Institute of Cardiology, ‘G. d’Annunzio’ University, Chieti, Italy |
| Deirdre A. Lane | Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom; and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark |
| Torben B. Larsen | Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark |
| Francisco Marin | Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain |
| Tatjana Potpara | School of Medicine, Belgrade University; Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia |
| Nizal Sarrafzadegan | Isfahan cardiovascular Research Center (WHO Collaborating Center), Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran; and School of Population and Public Health, University of British Columbia, Vancouver, Canada |
| Bianca Rocca (Co-Chair) (Italy) | Department of Pharmacology, Catholic University School of Medicine, Rome, Italy |
| Jean Philippe Collet | ACTION Study Group (www.action-coeur.org), Institut de Cardiologie Hôpital Pitié-Salpêtrière (APHP), Sorbonne Université Paris 6, INSERM UMRS 1166 Paris, France |

***Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease***

Lip et al.

1231

**From WG on Thrombosis:**

| Blanca Rocca (Co-Chair) (Italy) | Department of Pharmacology, Catholic University School of Medicine, Rome, Italy |

(Continued)
References


Lip et al. 2017

Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014;35(45):3155–3179

Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease Lip et al. 2017


van Hagen IM, Roos-Hesselink JW, Ruys TP, et al; ROPAC (Registry of Valvular Heart Disease of the European Society of Cardiology) registry. Indian Heart J 2017;69(1):43–47


Desai CS, Bonow RO. Transcatheter valve replacement for aortic stenosis: balancing benefits, risks, and expectations. JAMA 2012;308(06):573–574

Tilquin CN, Maddox TM. Cardiac crossroads: deciding between mechanical or bioprosthetic heart valve replacement. Patient Prefer Adherence 2011;5:91–99


Charles C, Gafni A, Whelan T. How to improve communication between doctors and patients. Learning more about the decision-making context is important. BMJ 2000;320(7244):1220–1221


